(3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-[1H]-hexahydrobenzo[e]isoindole hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-[1H]-hexahydrobenzo[e]isoindole hydrochloride
• 英文别名: (3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]isoindole hydrochloride；(3aR,9bR)-6-Methoxy-2,3,3a,4,5,9b-[1H]-hexahydrobenz[e]isoindole hydrochloride；(3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]isoindole;hydrochloride
• 化学式: C₁₃H₁₇NO*ClH
• 分子量: 239.745
• InChiKey: SGMRZWNYQUCOKI-PKKHVXKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  25.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-[1H]-hexahydrobenzo[e]isoindole hydrochloride 在 三溴化硼 作用下， 以 CH2 Cl 、 二氯甲烷 为溶剂， 以4.9g (87%)的产率得到(3aR,9bR)-6-Hydroxy-2,3,3a,4,5,9b-[1H]-hexahydrobenz[e]isoindole hydrobromide
  参考文献：
  名称：

  Bicyclic substituted hexahydrobenz \x9be! isoindole alpha-1 adrenergic

  摘要：

  本发明涉及以下公式的化合物##STR1##及其药用可接受的盐，其中W是一个双环杂环环系统。这些化合物是α-1肾上腺素受体拮抗剂，在治疗BPH方面具有用途；还公开了α-1拮抗剂组合物和对抗α-1受体以及治疗BPH的方法。

  公开号：

  US05792767A1
• 作为产物：
  描述：

  (3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-[1H]-hexahydrobenzo[e]isoindole 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 (3aR,9bR)-6-methoxy-2,3,3a,4,5,9b-[1H]-hexahydrobenzo[e]isoindole hydrochloride
  参考文献：
  名称：

  三氟甲磺酸铜(I)存在下钯催化环状烯烃的不对称双(烷氧基羰基化)反应

  摘要：

  在三氟甲磺酸铜 (I) 存在下，钯催化的 1,2-二氢萘和相关环烯烃的不对称双（烷氧基羰基化）反应是通过使用手性双恶唑...

  DOI：

  10.1246/bcsj.20120125

文献信息

• Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic
  申请人：Abbott Laboratories

  公开号：US05597823A1

  公开（公告）日：1997-01-28

  The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an .alpha.-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

  本发明涉及一种具有以下结构的化合物##STR1##及其药用可接受的盐，其中W是一个三环杂环环系统；它是一种α-1肾上腺素受体拮抗剂，对治疗BPH有用；还公开了α-1拮抗剂组合物和拮抗α-1受体并治疗BPH的方法。
• Bicyclic substituted hexahydrobenz[e]isoindole .alpha.-1 adrenergic
  申请人：Abbott Laboratories

  公开号：US05521181A1

  公开（公告）日：1996-05-28

  The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

  本发明涉及一种具有以下结构的化合物##STR1##及其药学上可接受的盐，其中W是一个双环杂环环系统。这些化合物是α-1肾上腺能拮抗剂，可用于治疗前列腺增生症；还公开了α-1拮抗剂组合物以及拮抗α-1受体和治疗前列腺增生症的方法。
• Asymmetric Bis(alkoxycarbonylation) Reaction of Cyclic Olefins Catalyzed by Palladium in the Presence of Copper(I) Triflate
  作者：Takahiro Aratani、Kenji Tahara、Susumu Takeuchi、Satoko Kitamura、Moemi Murai、Shuhei Fujinami、Katsuhiko Inomata、Yutaka Ukaji

  DOI：10.1246/bcsj.20120125

  日期：2012.11.15

  A palladium-catalyzed asymmetric bis(alkoxycarbonylation) reaction of 1,2-dihydronaphthalenes and related cyclic olefins in the presence of copper(I) triflate was achieved by using a chiral bioxazo...

  在三氟甲磺酸铜 (I) 存在下，钯催化的 1,2-二氢萘和相关环烯烃的不对称双（烷氧基羰基化）反应是通过使用手性双恶唑...
• [EN] TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS<br/>[FR] ANTAGONISTES ALPHA-1-ADRENERGIQUES D'HEXAHYDROBENZEISOINDOL TRICYCLIQUE SUBSTITUE
  申请人：ABBOTT LABORATORIES

  公开号：WO1996022992A1

  公开（公告）日：1996-08-01

  (EN) The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an $g(a)-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are $g(a)-1 antagonist compositions and a method for antagonizing $g(a)-1 receptors and treating BPH.(FR) La présente invention concerne un composé, ainsi que ses sels acceptables sur le plan pharmaceutique, correspondant à la formule (I) où W est un système de noyau hétérocyclique tricyclique. Ce composé est un antagoniste $g(a)-1 adrénergique utile dans le traitement de l'hyperplasie prostatique bénigne. Cette invention concerne également des compositions à base d'antagoniste $g(a)-1 ainsi qu'un procédé visant à rendre antagonistes des récepteurs $g(a)-1, et utilisé dans le traitement de l'hyperplasie prostatique bénigne.

  本发明涉及化合物(I)及其在药学上可接受的盐，其中W是三环杂环环系统；该化合物是$g(a)-1肾上腺素受体拮抗剂，用于治疗BPH；此外还揭示了$g(a)-1拮抗剂组合物以及拮抗$g(a)-1受体和治疗BPH的方法。
• Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[<i>e</i>]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia
  作者：Michael D. Meyer、Robert J. Altenbach、Hao Bai、Fatima Z. Basha、William A. Carroll、James F. Kerwin、Suzanne A. Lebold、Edmund Lee、John K. Pratt、Kevin B. Sippy、Karin Tietje、Michael D. Wendt、Michael E. Brune、Steven A. Buckner、Arthur A. Hancock、Irene Drizin

  DOI：10.1021/jm000541z

  日期：2001.6.1

  In search of a uroselective alpha (1A) subtype selective antagonist, a novel series of 6-OMe hexahydrobenz [e]isoindoles attached to a bicyclic heterocyclic moiety via a two-carbon linker was synthesized. It was found that in contrast to the previously described series of tricyclic heterocycles,l this bicyclic series has very specific requirements for the heterocyclic attachments. The most important structural features contributing to the alpha (1A)/alpha (1B) selectivity of these compounds were identified. In vitro functional assays for the al adrenoceptor subtypes were used to further characterize the most selective compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity. Compound 48 showed the highest degree of selectivity in the radioligand binding assays (56-fold), in the in vitro functional tests (80-fold), and for in vivo prostate selectivity (960-fold).